Regeneron Pharmaceuticals Inc - REGN STOCK NEWS

Regeneron Pharmaceuticals (NASDAQ: REGN) announced nearly 30 presentations on Dupixent at AAD VMX 2021 and ESPD 2021. The data highlights Dupixent's effectiveness in providing rapid itch relief and improving disease severity in patients as young as 6 years old with moderate-to-severe atopic dermatitis. Clinical trials showed long-term efficacy and a favorable safety profile, with lower infection rates compared to placebo. Key findings include significant improvements in quality of life and disease measures across various age groups, supporting Dupixent's essential role in managing atopic dermatitis.

Regeneron Pharmaceuticals announced positive results from its Phase 3 trial evaluating REGEN-COV in asymptomatic COVID-19 patients. The trial reported a 31% reduction in the risk of progressing to symptomatic COVID-19 and a 76% reduction after three days. Among 204 participants, the treatment also shortened symptom duration by 45% and reduced viral levels by more than 90%. There were no hospitalizations among REGEN-COV patients compared to 6% in the placebo group. This trial reinforces REGEN-COV's potential for early intervention in non-hospitalized COVID-19 cases.

Regeneron Pharmaceuticals announced positive results from a Phase 3 trial for REGEN-COV, demonstrating an 81% reduction in symptomatic COVID-19 infections among household contacts of infected individuals. Administered as a 1,200 mg subcutaneous dose, REGEN-COV provided 72% protection in the first week and 93% thereafter. Participants who contracted COVID-19 experienced faster symptom resolution compared to the placebo group. Regeneron plans to submit these findings to the FDA for Emergency Use Authorization to expand REGEN-COV's application in COVID-19 prevention.

Regeneron Pharmaceuticals (NASDAQ: REGN) announced that the NIH COVID-19 Treatment Guidelines now strongly recommend REGEN-COV™ (casirivimab with imdevimab) for non-hospitalized COVID-19 patients at high risk of clinical progression. This strong 'AIIa' rating is based on clinical trials involving over 4,500 outpatients, showing a 70% reduction in hospitalization or death risk. The FDA has issued Emergency Use Authorization for REGEN-COV, which retains potency against emerging COVID-19 variants. Regeneron aims to improve access and explore simpler administration methods for REGEN-COV.

Regeneron Pharmaceuticals (NASDAQ: REGN) will announce its first quarter 2021 financial results on May 6, 2021, prior to market opening. A conference call will be held at 8:30 AM ET to discuss the results. Participants can join by dialing (888) 660-6127 (U.S.) or (973) 890-8355 (International) with conference ID 7794757. Regeneron is a biotech leader known for producing transformative treatments for serious diseases, leveraging advanced technologies like VelociSuite® and the Regeneron Genetics Center.

Data from the Protocol W trial confirms findings from the PANORAMA trial, demonstrating that EYLEA (aflibercept) injections significantly decrease vision-threatening complications in diabetic retinopathy patients. The study revealed a 68% lower risk of serious vision loss in patients receiving EYLEA every 16 weeks compared to sham. Although overall vision acuity was similar at two years, those delaying EYLEA experienced three times the prolonged vision loss. Regeneron plans to consult the FDA regarding this new dosing regimen.

Regeneron Pharmaceuticals announced positive topline results from a Phase 3 trial of REGEN-COV for non-hospitalized COVID-19 patients, involving 4,567 participants. The treatment significantly reduced hospitalization/death risk by 70% (1,200 mg) and 71% (2,400 mg) compared to placebo. Additionally, REGEN-COV shortened symptom duration by an average of 4 days. The FDA updated EUA fact sheets confirming REGEN-COV's potency against emerging variants. Regeneron plans to seek EUA for the lower 1,200 mg dose. First-quarter sales are projected at $260 million to the U.S. government, with an increased supply expectation.

Regeneron Pharmaceuticals (NASDAQ: REGN) and Society for Science announced the winners of the 2021 Regeneron Science Talent Search, awarding over $1.8 million to 40 finalists. Yunseo Choi from New Hampshire secured the top prize of $250,000 for her research on matching algorithms. Other notable winners included Noah Getz and Eshani Jha, who received $175,000 and $150,000 respectively, for projects in drug discovery and water filtration. Regeneron's ongoing commitment to education includes a $100 million pledge to support STEM initiatives.

Regeneron Pharmaceuticals and Sanofi announced positive results for Libtayo in a Phase 3 trial for recurrent or metastatic cervical cancer, showing a 31% reduction in the risk of death compared to chemotherapy. The median overall survival was 12.0 months for Libtayo versus 8.5 months for chemotherapy. The trial was halted early due to a unanimous recommendation from the Independent Data Monitoring Committee. Regulatory submissions are planned for 2021. Libtayo has already demonstrated clinical benefits in four cancer types.